FDA Hosts Public Workshop on Developing Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

Summary

The FDA is hosting a public workshop to discuss challenges and future directions for inhaled antibacterial products to treat cystic fibrosis and non-cystic fibrosis bronchiectasis, following a request for comments on the topic.